JP2009519720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519720A5 JP2009519720A5 JP2008546030A JP2008546030A JP2009519720A5 JP 2009519720 A5 JP2009519720 A5 JP 2009519720A5 JP 2008546030 A JP2008546030 A JP 2008546030A JP 2008546030 A JP2008546030 A JP 2008546030A JP 2009519720 A5 JP2009519720 A5 JP 2009519720A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dab
- recombinant
- disease
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 17
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 8
- 102000057041 human TNF Human genes 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 241000288935 Platyrrhini Species 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000011379 keloid formation Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 241000282709 Aotus trivirgatus Species 0.000 description 6
- 241001515942 marmosets Species 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000282708 Aotus <primate> Species 0.000 description 1
- 241001502973 Aotus nancymaae Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005907124A AU2005907124A0 (en) | 2005-12-20 | Anti-inflammatory dAb | |
| AU2005907124 | 2005-12-20 | ||
| US81727206P | 2006-06-28 | 2006-06-28 | |
| US60/817,272 | 2006-06-28 | ||
| PCT/AU2006/001940 WO2007070948A1 (en) | 2005-12-20 | 2006-12-20 | Anti-inflammatory dab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009519720A JP2009519720A (ja) | 2009-05-21 |
| JP2009519720A5 true JP2009519720A5 (cg-RX-API-DMAC7.html) | 2010-06-17 |
| JP5179374B2 JP5179374B2 (ja) | 2013-04-10 |
Family
ID=38188157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546030A Expired - Fee Related JP5179374B2 (ja) | 2005-12-20 | 2006-12-20 | 抗炎症ドメイン抗体（ｄＡｂ） |
| JP2008546037A Pending JP2009519983A (ja) | 2005-12-20 | 2006-12-20 | 部分的な新世界ザル結合領域を有するキメラ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546037A Pending JP2009519983A (ja) | 2005-12-20 | 2006-12-20 | 部分的な新世界ザル結合領域を有するキメラ抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US7981414B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1969010A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5179374B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080080651A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2006326937B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2634083A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA017710B1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2007070979A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006281980A1 (en) * | 2005-08-15 | 2007-02-22 | Cephalon Australia Pty Ltd | Engineered antibodies with new world primate framework regions |
| US7981414B2 (en) * | 2005-12-20 | 2011-07-19 | Cephalon Australia Pty Ltd | Anti-inflammatory dAb |
| WO2007087673A1 (en) | 2006-02-01 | 2007-08-09 | Arana Therapeutics Limited | Domain antibody construct |
| US20080139790A1 (en) * | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
| WO2010017595A1 (en) * | 2008-08-14 | 2010-02-18 | Arana Therapeutics Limited | Variant domain antibodies |
| CN104013724A (zh) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | 一种改善睡眠的中药组合物 |
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| ES2973042T3 (es) | 2015-03-31 | 2024-06-18 | Sorriso Pharmaceuticals Inc | Polipéptidos |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| CN107469069A (zh) * | 2017-08-18 | 2017-12-15 | 四川普莱美生物科技集团有限公司 | 恒河猴肺纤维化模型的造模方法、制剂、制剂的制备方法、恒河猴肺纤维化模型及其应用 |
| CN110003330B (zh) * | 2019-04-12 | 2022-09-09 | 深圳普瑞金生物药业股份有限公司 | TNF-α单域抗体、核酸分子及试剂盒 |
| CN114466864B (zh) | 2019-06-21 | 2024-12-27 | 索瑞索制药公司 | 多肽 |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
| RO116404B1 (ro) * | 1991-07-25 | 2001-01-30 | Idec Pharmaceuticals Corp San | Anticorp recombinant, acid nucleic care il codifica, procedeu de obtinere a anticorpului recombinant si metoda de tratament cu acesta |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| US7235643B2 (en) * | 2000-11-07 | 2007-06-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with high affinity |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| GB0114856D0 (en) * | 2001-06-18 | 2001-08-08 | Medical Res Council | Selection by avidity capture |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| CN1671416B (zh) * | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DK1527100T3 (da) * | 2002-03-29 | 2009-09-07 | Schering Corp | Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
| GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| DE602004022390D1 (de) | 2003-03-26 | 2009-09-17 | Apogenix Gmbh | Verbesserte fc-fusionsproteine |
| US20090005257A1 (en) * | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| CN1836041A (zh) | 2003-06-27 | 2006-09-20 | 比奥伦公司 | 浏览突变 |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| CN103880955A (zh) * | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
| US20070212301A1 (en) | 2003-11-07 | 2007-09-13 | Amgen, Inc. | Monkey Immunoglobulin Sequences |
| WO2005052002A2 (en) * | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| DK1718677T3 (da) | 2003-12-19 | 2012-07-09 | Genentech Inc | Monovalente antistoffragmenter egnede som terapeutiske midler |
| CA2558811A1 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
| US6979473B2 (en) | 2004-03-15 | 2005-12-27 | Boston Scientific Scimed, Inc. | Method for fine bore orifice spray coating of medical devices and pre-filming atomization |
| US20060024308A1 (en) * | 2004-07-06 | 2006-02-02 | Roberto Crea | High affinity anti-TNF-alpha antibodies and method |
| CN101171263A (zh) | 2005-03-04 | 2008-04-30 | 比奥根艾迪克Ma公司 | 通过合理修饰互补决定区残基使免疫球蛋白可变区人源化的方法 |
| EP1874816A4 (en) | 2005-04-26 | 2010-08-25 | Medimmune Inc | MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING |
| EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| AU2006281980A1 (en) | 2005-08-15 | 2007-02-22 | Cephalon Australia Pty Ltd | Engineered antibodies with new world primate framework regions |
| US7981414B2 (en) | 2005-12-20 | 2011-07-19 | Cephalon Australia Pty Ltd | Anti-inflammatory dAb |
| WO2007087673A1 (en) | 2006-02-01 | 2007-08-09 | Arana Therapeutics Limited | Domain antibody construct |
| WO2007092772A2 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
| BRPI0710011A2 (pt) * | 2006-04-14 | 2011-08-02 | Trubion Pharmaceuticals Inc | proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas |
| US20080139790A1 (en) | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
| EP2144930A1 (en) * | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
| AR069495A1 (es) * | 2007-11-30 | 2010-01-27 | Glaxo Group Ltd | Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis) |
| AU2009206149B2 (en) * | 2008-01-16 | 2013-07-18 | Mars, Incorporated | Automated systems for feeding animals and collecting animal excrement |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| EP2288623B1 (en) | 2008-05-23 | 2013-07-10 | Ablexis, LLC | Method of generating single vl domain antibodies in transgenic animals |
-
2006
- 2006-12-20 US US11/659,009 patent/US7981414B2/en not_active Expired - Fee Related
- 2006-12-20 JP JP2008546030A patent/JP5179374B2/ja not_active Expired - Fee Related
- 2006-12-20 JP JP2008546037A patent/JP2009519983A/ja active Pending
- 2006-12-20 WO PCT/AU2006/001993 patent/WO2007070979A1/en not_active Ceased
- 2006-12-20 US US12/158,034 patent/US20090286962A1/en not_active Abandoned
- 2006-12-20 AU AU2006326937A patent/AU2006326937B2/en not_active Ceased
- 2006-12-20 AU AU2006326867A patent/AU2006326867A1/en not_active Abandoned
- 2006-12-20 EA EA200870072A patent/EA017710B1/ru not_active IP Right Cessation
- 2006-12-20 EP EP06828046A patent/EP1969010A4/en not_active Withdrawn
- 2006-12-20 CA CA002634083A patent/CA2634083A1/en not_active Abandoned
- 2006-12-20 CA CA002634080A patent/CA2634080A1/en not_active Abandoned
- 2006-12-20 WO PCT/AU2006/001940 patent/WO2007070948A1/en not_active Ceased
- 2006-12-20 KR KR1020087017659A patent/KR20080080651A/ko not_active Ceased
- 2006-12-20 EP EP06840403A patent/EP1969009A4/en not_active Withdrawn
-
2011
- 2011-01-18 US US13/008,342 patent/US8263076B2/en not_active Expired - Fee Related
-
2012
- 2012-08-14 US US13/585,192 patent/US20130040383A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5513888B2 (ja) | グルカゴン受容体抗体に関する組成物および方法 | |
| TWI436778B (zh) | Ｉｌ－１８受體抗原結合蛋白 | |
| JP2009519720A5 (cg-RX-API-DMAC7.html) | ||
| US8263076B2 (en) | Anti-inflammatory dAb | |
| US9708402B2 (en) | Anti-BAFF-anti-IL-17 bispecific antibodies | |
| JP5836130B2 (ja) | ヒトｉｌ−１３に結合特異性を有する抗体分子 | |
| JP2009513712A5 (cg-RX-API-DMAC7.html) | ||
| US20130171146A1 (en) | Dual-specific il-1a/ il-1b antibodies | |
| JP2014503209A5 (cg-RX-API-DMAC7.html) | ||
| JP2008542278A5 (cg-RX-API-DMAC7.html) | ||
| JP2020506898A5 (cg-RX-API-DMAC7.html) | ||
| JP2005530490A5 (cg-RX-API-DMAC7.html) | ||
| JP2009165471A (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| BRPI0707425A2 (pt) | construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio | |
| CN108473568A (zh) | 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子 | |
| KR20220063221A (ko) | Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용 | |
| JP6949012B2 (ja) | Ｂ型肝炎表面抗原に対する抗体及びその使用 | |
| JP2020519562A (ja) | 抗インターフェロンガンマ抗体およびその使用法 | |
| WO2021008519A1 (zh) | ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用 | |
| CN101287762A (zh) | 具有新世界灵长类构架区的经改造的抗体 | |
| EP3689906B1 (en) | Il-5 antibody or antigen binding fragment thereof in medical application | |
| KR20200133365A (ko) | Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용 | |
| CN118085082A (zh) | 抗猫TNF-α单克隆抗体及其应用 | |
| RU2800370C2 (ru) | Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение | |
| JP2010507362A (ja) | 天然痘モノクローナル抗体 |